<div id="readability-page-1"><h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Sino Biopharmaceutical ( (HK:1177) ) has shared an update. Sino Biopharmaceutical said its subsidiary Chia Tai Tianqing has secured U.S. FDA clearance for an investigational new drug application for TQB3205, an oral pan-KRAS inhibitor for advanced malignant tumors. The molecule is designed to bind multiple KRAS-mutant proteins with high affinity, locking them in an inactive state and blocking downstream signaling pathways such as MAPK and PI3K-AKT to curb proliferation of KRAS-mutant tumor cells. KRAS mutations are implicated in about 30% of cancers worldwide, including high rates in pancreatic, colorectal and non-small cell lung cancers, yet currently approved KRAS drugs only target the G12C subtype. By advancing TQB3205, which aims to address a broader spectrum of KRAS mutations, alongside its already approved G12C inhibitor Garsorasib in China, Sino Biopharmaceutical is deepening its strategic footprint in KRAS-targeted oncology and positioning itself to serve a wider patient population with significant unmet needs. The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. More about Sino Biopharmaceutical Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group engaged in the research, development and commercialization of innovative drugs. Through subsidiaries such as Chia Tai Tianqing Pharmaceutical Group, the company focuses on oncology and other high-incidence therapeutic areas, with a growing portfolio of targeted therapies aimed at major unmet medical needs. Average Trading Volume: 69,787,707 Technical Sentiment Signal: Buy Current Market Cap: HK$113.2B For an in-depth examination of 1177 stock, go to TipRanks’ Overview page.</div>

560600

512290

159849

Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has received FDA approval for TQB3205, an oral pan-KRAS inhibitor targeting advanced malignant tumors. This drug aims to address a wider range of KRAS mutations, which are linked to about 30% of cancers globally. The company is expanding its oncology portfolio, complementing its existing G12C inhibitor, Garsorasib. Analysts rate Sino Biopharmaceutical (HK:1177) as a Buy with a price target of HK$8.70. The company focuses on innovative drug development in oncology and other therapeutic areas, with a market cap of HK$113.2B.

Tip Ranks

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

SIHUAN PHARM PREF OFFER

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

SBP GROUP

E Fund Hang Seng SCHK Innovative Drug ETF

Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205